Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERUSE: Pertuzumab + Trastuzumab + Taxane in HER2+ Advanced Breast Cancer
NCT01572038Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2012
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 39
01
Overview
Phase 3, open-label, single-arm trial of pertuzumab in HER2-positive breast cancer, sponsored by Roche. Primary endpoints: Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event up to 86.4 months, Number of Participants Who Died Over the Course of the Study up to 87.29 months and 3 more. Started Jun 2012; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01572038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572038.